Phase I Double-blind, Placebo-controlled Study of AZD7442

Study identifier:D8850C00005

ClinicalTrials.gov identifier:NCT04896541

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Phase I Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD7442 in Healthy Japanese Participants

Medical condition

COVID-19

Phase

Phase 1

Healthy volunteers

Yes

Study drug

-

Sex

All

Actual Enrollment

40

Study type

Interventional

Age

18 Years - 55 Years

Date

Study Start Date: 16 Mar 2021
Primary Completion Date: 14 Jun 2022
Study Completion Date: 14 Jun 2022

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Prevention

Verification:

Verified 01 Jun 2022 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria